Influencia de la puntuación MELD basal en la eficacia del tratamiento de la hepatitis C con sofosbuvir y simeprevir

Moreno-Planas, José María; Larrubia-Marfil, Juan Ramón; Sánchez-Ruano, Juan José; Morillas-Ariño, Julia; Patón-Arenas, Roberto; Sáiz-Chumillas, Rosa María; Tébar-Romero, Emilia; Lucendo-Villarín, Alfredo; Gancedo-Bringas, Pilar; Solera-Muñoz, Mario; Vicente-Gutiérrez, María del Mar; Martínez-Alfaro, Elisa.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 36(5): 277-283, mayo 2018. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-176568

Documentos relacionados

  1. Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line.
  2. Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience.
  3. Influence of baseline MELD score in the efficacy of treatment of hepatitis C with simeprevir and sofosbuvir.
  4. New medications for treatment of chronic hepatitis C.
  5. Treatment of chronic hepatitis C with direct-acting antivirals in patients with ß-thalassaemia major and advanced liver disease.
  6. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
  7. Which therapeutic option for hepatitis C virus genotype 1?
  8. Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C.
  9. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.
  10. Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil.